T1	Claim 1526 1647	combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
T2	Premise 983 1044	Partial response rates were 40 and 41.7% in IEP and MVP arms.
T3	Premise 1045 1185	Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).
T4	Premise 1186 1275	One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.
T5	Premise 1276 1366	Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.
T6	Premise 1367 1508	Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.
R1	Support Arg1:T3 Arg2:T1	
R2	Support Arg1:T4 Arg2:T1	
R3	Support Arg1:T5 Arg2:T1	
R4	Support Arg1:T6 Arg2:T1	
